This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The three screening strategies were examined were: PCR screening for all patients (universal); screening for risk factors (prior hospitalisation or antibiotic use) combined with pre-emptive isolation and contact precautions pending chromogenic agar results; and no screening (standard surgical admission without MRSA screening on admission).
Location/setting
Switzerland/hospital.
Methods

Analytical approach:
The analysis was based on a decision tree Markov model with a short-term horizon (period of hospitalisation). The authors stated that the study was carried out from the perspective of the hospital administrator.
Effectiveness data:
Most clinical inputs for rapid PCR and no surveillance strategies came from a large, prospective cohort study (Harbarth, et al. 2008 , see 'Other Publications of Related Interest' below for bibliographic details) that was carried out at the authors' institution (University of Geneva Hospital, Switzerland). Data on screening for risk factors came from published studies including clinical trials. The median turnaround time of PCR and agar tests were estimated at the authors' institution. Sensitivity and specificity of rapid PCR tests were taken from the cohort study and were the primary endpoints of the clinical analysis.
Monetary benefit and utility valuations:
Not considered.
Measure of benefit:
The rate of MRSA infections avoided was used as the summary benefit measure.
Cost data:
The costs included screening (personnel, materials, and overhead), decolonisation, hospital stay, and other tests. All costs were taken from the accounting system of the authors' institution. Resource quantities were based on data from
